Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Should I Buy Pearson PLC (PSO)?

LONDON — It’s time to go shopping for shares again, but where to start? There are loads of great FTSE 100 stocks to choose from, and I’ve got my wallet out. So should I buy Pearson PLC (ADR) (NYSE:PSO) ?

A tale of three divisions
While Pearson is best known as the owner of the Financial Times and Penguin, two-thirds of its revenues come from its lesser-known educational division. Its share price has suffered a turbulent 12 months, due to rising fears over its growth prospects, and I’m wondering whether this could be a good entry point.

Pearson PLC (ADR) (NYSE:PSO)Education, education, education
Pearson’s recent trading update, published in January, disappointed the market. Its share price fell 3% after it warned that a slack Q4 would hit 2012 earnings from higher education, consumer publishing and corporate advertising, and 2013 looks set to remain weak. Its profits were also dented by the sale of FTSE International, which contributed 20 million pounds in 2011, and its decision to close adult educational business Pearson In Practice, which it acquired in 2010 for around 100 million pounds.

Them and U.S.
But it wasn’t all bad news. Pearson reported steady revenue growth and a 935 million-pound operating profit last year. It anticipates “modest revenue growth” in its U.S. education business, where it generates around 60% of its sales, and strong market share growth. That’s more impressive than it sounds, because these are tough times for the U.S. educational materials industry. If sterling continues to fall against the dollar, Pearson could enjoy a boost in currency adjusted earnings from this division in 2012. Its educational arm is also growing strongly in emerging markets, although maybe not strongly enough to compensate for weakness elsewhere.

Pick up a Penguin?
Penguin enjoyed a strong fourth quarter, defying the doom-mongers, who have been exaggerating the death of the physical book retail market for years. Newspaper publishing is another industry that has been written off, and the news here wasn’t so good, with the Financial Times suffering a drop in full-year profits. I happen to think the Financial Times is better placed than any other U.K. newspaper to make the shift from print to digital. Its readers should be more willing to pay for its specialist premium content, especially since many will be able to claim it as a business expense. But the short-term cost of making that shift has hit profits. Last autumn, there was plenty of press talk about Pearson selling the FT. Since denied, a sale would raise around 1 billion pounds, which would boost the stock. So it may be worth hanging on for that.

Pearson is a well-run business, but it clearly faces a lot of challenges. Earnings per share growth of 5% this year and 9% next year would be a solid return, given the various headwinds the company faces. The big brokers have been reducing their target prices and downgrading the stock from buy to hold, and it isn’t hard to see why. Trading on a FTSE 100 average yield of 3.5% and a slightly below average valuation of 13.9 times earnings, Pearson looks like reasonable value, but management has a battle on its hands to deliver crowd-pleasing growth.

The article Should I Buy Pearson? originally appeared on and is written by Harvey Jones.

Harvey doesn’t own any shares mentioned in this article.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!